The core goods of this project cover three mainstream peptide raw materials and oral formulations dominating the global metabolic health track: semaglutide, retatrutide and tirzepatide. All three fall under the GLP‑1 receptor agonist category yet feature distinct differences in target structure, clinical efficacy and product positioning, forming an optimal stocking portfolio for overseas distributors.Semaglutide is a long‑acting single‑target GLP‑1 peptide originally developed by Novo Nordisk. It is the world's first peptide drug approved simultaneously for type 2 diabetes mellitus, obesity and weight management, as well as cardiovascular protection, with its original formulation primarily presented as injections. Tirzepatide acts as a dual GLP‑1/GIP receptor agonist. The synergistic activation of two receptors delivers superior weight loss and blood glucose lowering effects compared to single‑target Semaglutide. Retatrutide represents a new‑generation triple‑target (GLP‑1/GCG/GIP) peptide drug candidate currently undergoing Phase III clinical trials, with clinical data demonstrating industry‑leading weight loss potency.
|
|
|
|
|
|
|
|
Overview of Procurement & Cooperation
The partner for this project is a long‑term, reliable client based in California, USA. Both parties have established a track record of multiple cross‑border supply collaborations for peptide formulations.
The client owns well‑developed offline distribution networks across North America and consistently procures oral GLP‑1 peptide formulations to supply local healthcare institutions and weight management clinics.
This bulk order fulfills the client's comprehensive stocking needs, with a fully closed‑loop workflow covering consultation, quotation, payment, warehousing and cross‑border logistics, which fully demonstrates the standardized export service workflow for peptide formulations.
At the initial communication stage, the client specified the required product portfolio: oral semaglutide ( https://en.wikipedia.org/wiki/Semaglutide) capsules, 40mg retatrutide (https://en.wikipedia.org/wiki/Retatrutide) and 60mg tirzepatide (https://en.wikipedia.org/wiki/Tirzepatide). Our initial quotation was calculated as follows: USD 840 for 500 pieces of 7mg Semaglutide capsules; USD 400 per box for 2 boxes of 60mg Retatrutide; USD 210 per box for 2 boxes of 60mg Tirzepatide. Cross‑border logistics and customs clearance fees for the four batches of goods totaled USD 85, bringing an initial aggregate amount of USD 2,145.
Subsequently, the client requested a specification adjustment for Retatrutide from 60mg to 40mg. We promptly revised the quotation, adjusting the unit price of 40mg Retatrutide to USD 330 per box.
The revised order totaled USD 2,005, and the client finalized payment with a rounded lump sum of USD 2,000 upon confirmation.
Upon receipt of full payment, we initiated split filling, packaging and outbound shipment procedures for two separate consignments. On June 9, 2026, both batches of goods were dispatched simultaneously with fully traceable logistics records.
The client received all products intact without delivery discrepancies, customs detentions or goods damage, further solidifying the trust foundation for long‑term partnership.
Core Application Sectors of the Products
1. Clinical Intervention for Metabolic Disorders
The fundamental primary application of the three peptides is glycemic control in type 2 diabetes. By activating intestinal GLP‑1 receptors, they slow gastric emptying, suppress secretion of hyperglycemic hormones, stabilize postprandial blood glucose, reduce glycated hemoglobin levels and ameliorate insulin resistance, making them suitable for long‑term intervention in patients with concurrent obesity and diabetes.
Unlike conventional hypoglycemic agents, peptide products carry no risk of hypoglycemia and boast prominent safety advantages, leading to rising adoption rates in endocrinology clinical practice across the United States.
2. Weight Management & Obesity Intervention
Weight loss constitutes the core growth driver of market demand for all three products.Over 40% of the U.S. population suffers from obesity, generating robust demand from offline weight loss clinics and wellness service outlets.
Oral Semaglutide capsules are suitable for daily weight maintenance among mild and moderately obese populations;
Tirzepatide's dual‑target mechanism enables rapid weight reduction for moderate to severe obesity;
Retatrutide delivers potent triple‑target weight loss effects, ideal for severely obese patients and preoperative conditioning prior to bariatric surgery.
This tiered product lineup addresses the full spectrum of weight management scenarios.
3. Adjuvant Relief of Obesity‑Related Complications
Beyond glycemic control and weight reduction, these peptides boast expanded derivative therapeutic applications:
Tirzepatide has obtained U.S. approval for treating moderate to severe obstructive sleep apnea in obese patients;
Clinical data of Retatrutide validate its efficacy in alleviating knee inflammation and joint pain triggered by obesity;
Semaglutide lowers cardiovascular disease risk among obese populations.
The expanding diversified indications of the three products continuously broaden end‑user application scenarios and boost profit margins for channel distributors.
4. Raw Material Supply for Cross‑Border Wellness Retail & Institutional Clients
The purchasing client is a North American distributor supplying offline weight loss clinics, functional wellness retail stores and private health management institutions. Oral capsules eliminate the need for professional injection administration, presenting a low usage barrier for end consumers and far higher repurchase rates than injectable formulations, rendering them top‑selling commodities in cross‑border trade channels.
OEM Customization Service
BLOOM Tech specializes in OEM customization of peptide tablets and oral capsules, supporting custom formulations with various active ingredient dosages and accepting small-batch orders. We have independently developed stable compound formulas that use compliant excipients including corn starch and magnesium stearate to effectively enhance the gastric acid resistance of peptides.
Every batch undergoes comprehensive quality inspections covering purity, microbiological indicators and heavy metals, with complete shipment documents provided.
We offer full packaging customization including aluminum foil bags, sealed storage boxes and cross-border protective cartons, compatible with North American dedicated logistics such as USPS and FedEx.
Our one-stop services cover filling & packaging, logistics documentation and customs clearance support, with split-parcel delivery and separate tracking numbers available.
We have long-term cooperation with US overseas distributors and accommodate cross-border wire transfer payment procedures. With standardized quality control and stable lead times, we comprehensively cut down inventory and cross-border distribution operating costs for overseas clients.
